[go: up one dir, main page]

PE20050676A1 - Quinolinas referidas a enfermedades cardiovasculares - Google Patents

Quinolinas referidas a enfermedades cardiovasculares

Info

Publication number
PE20050676A1
PE20050676A1 PE2004001236A PE2004001236A PE20050676A1 PE 20050676 A1 PE20050676 A1 PE 20050676A1 PE 2004001236 A PE2004001236 A PE 2004001236A PE 2004001236 A PE2004001236 A PE 2004001236A PE 20050676 A1 PE20050676 A1 PE 20050676A1
Authority
PE
Peru
Prior art keywords
alkyl
quinolines
referred
cardiovascular diseases
trifluorometil
Prior art date
Application number
PE2004001236A
Other languages
English (en)
Inventor
Michael D Collini
Jr Robert R Singhaus
Baihua Hu
James W Jetter
Robert L Morris
David H Kaufman
Christopher P Miller
John W Ullrich
Rayomand J Unwalla
Jay E Wrobel
Elaine Quinet
Ponnal Nambi
Ronald C Bernotas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34704262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050676(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050676A1 publication Critical patent/PE20050676A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE R1 ES H, ALQUILO C1-C3; X1 ES ENLACE, ALQUILO C1-C5, C(O), ENTRE OTROS, R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; X2 ES ENLACE O -CH2-; R3 ES FENILO, NAFTILO, PIRIDINA, INDOL, ENTRE OTROS; R4, R5 Y R6 SON CADA UNO H, F; R7 ES H, ALQUILO C1-C4, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [4-(4-METOXIFENIL)-8-(TRIFLUOROMETIL)QUINOLIN-3-IL]-(FENIL)METANONA, [4-(4-METILFENIL)-8-(TRIFLUOROMETIL)QUINOLIN-3-IL]-(PIRIDIN-2-IL)METANONA Y PIRIDIN-2-IL{8-(TRIFLUOROMETIL)-4-[3-(TRIFLUOROMETIL)-FENIL]QUINOLIN-3-IL}METANONA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O INHIBICION DE LAS ENFERMEDADES MEDIADAS POR LOS RECEPTORES X DEL HIGADO (LXR)
PE2004001236A 2003-12-12 2004-12-10 Quinolinas referidas a enfermedades cardiovasculares PE20050676A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52900903P 2003-12-12 2003-12-12
US60029604P 2004-08-10 2004-08-10

Publications (1)

Publication Number Publication Date
PE20050676A1 true PE20050676A1 (es) 2005-11-02

Family

ID=34704262

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001236A PE20050676A1 (es) 2003-12-12 2004-12-10 Quinolinas referidas a enfermedades cardiovasculares

Country Status (18)

Country Link
US (1) US7576215B2 (es)
EP (2) EP2284157A1 (es)
JP (1) JP2007516258A (es)
KR (1) KR20070001922A (es)
AR (1) AR047329A1 (es)
AU (1) AU2004298486A1 (es)
BR (1) BRPI0417543A (es)
CA (1) CA2547518A1 (es)
CR (1) CR8410A (es)
EC (1) ECSP066635A (es)
IL (1) IL175892A0 (es)
NO (1) NO20062561L (es)
PA (1) PA8619901A1 (es)
PE (1) PE20050676A1 (es)
RU (1) RU2006124843A (es)
SV (1) SV2005001973A (es)
TW (1) TW200529845A (es)
WO (1) WO2005058834A2 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487776A4 (en) * 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
WO2003082205A2 (en) * 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
JP4471842B2 (ja) * 2002-03-27 2010-06-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー アミド化合物および該化合物を用いる方法
US7323494B2 (en) * 2002-03-27 2008-01-29 Smithkline Beecham Corporation Compounds and methods
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
WO2005102388A1 (ja) * 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US20070299092A1 (en) * 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
ES2438739T3 (es) 2005-06-28 2014-01-20 Daiichi Sankyo Company, Limited Procedimiento de prueba de ligando LXR
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
WO2007050271A2 (en) * 2005-10-25 2007-05-03 Wyeth 5-lipoxygenase modulators
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2008036238A2 (en) * 2006-09-19 2008-03-27 Wyeth Use of lxr modulators for the prevention and treatment of skin aging
MX2009002794A (es) * 2006-09-19 2009-03-30 Wyeth Corp Uso de agonistas lxr para el tratamiento de osteoartritis.
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
EP2099444A4 (en) * 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
US20090069373A1 (en) * 2007-02-28 2009-03-12 Wyeth Quinoline Acids
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CN101668737A (zh) * 2007-03-08 2010-03-10 普莱希科公司 Ppar活性化合物
ES2329639B1 (es) * 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
CA2690079C (en) * 2007-06-18 2016-01-26 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
BRPI0821315A2 (pt) * 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US8008306B2 (en) 2008-04-30 2011-08-30 Kowa Company, Ltd. Quinoline compounds
US8153634B2 (en) 2008-05-29 2012-04-10 Kowa Company, Ltd. Carbinol derivatives having cyclic linker
PL2303021T3 (pl) * 2008-06-16 2019-10-31 Univ Tennessee Res Found Związki do leczenia nowotworu
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
CN105152919A (zh) * 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
WO2010026771A1 (ja) * 2008-09-08 2010-03-11 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤
WO2010054229A1 (en) * 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
AU2009322170A1 (en) * 2008-12-05 2011-07-14 Medicines For Malaria Venture Compounds having antiparasitic or anti-infectious activity
JP5774984B2 (ja) 2009-04-29 2015-09-09 興和株式会社 ヘテロ環リンカーを有するカルビノール化合物
WO2010125402A1 (en) 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
JP2012531436A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
RU2425034C1 (ru) * 2010-01-11 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения производных (e)-4-(6,7-диметокси-2-метил-3-хинолил)-3-бутен-2-она
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
WO2012004748A1 (en) * 2010-07-08 2012-01-12 Wyeth Llc Novel quinoline esters useful for treating skin disorders
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도
ES2379242B1 (es) * 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromeno.
ES2941477T3 (es) 2012-08-13 2023-05-23 Univ Rockefeller Agonista de LXRbeta para el tratamiento de cáncer
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
EP2909193B1 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
CN103965105A (zh) * 2013-01-29 2014-08-06 中山大学 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用
WO2014123203A1 (ja) * 2013-02-06 2014-08-14 京都薬品工業株式会社 糖尿病治療薬
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016008257A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de roryt de álcool quinolínico secundário
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN104036909B (zh) * 2014-06-25 2016-09-28 桂林理工大学 磁性材料[Cu3(N3)6(DMF)2]n及合成方法
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3246028A1 (en) * 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN110621656A (zh) * 2017-05-12 2019-12-27 研究三角协会 作为cb1别构调节剂的二芳基脲
WO2019074241A1 (ko) * 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
EP4155300A1 (en) 2017-10-30 2023-03-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted quinoline analogs as aldehyde dehydrogenase 1a1 (aldh1a1) inhibitors
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2021076886A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
CN115666568A (zh) * 2019-11-15 2023-01-31 佐治亚州立大学研究基金会 小分子聚合酶抑制剂
RS65646B1 (sr) 2019-12-13 2024-07-31 Inspirna Inc Soli metala i njihove upotrebe
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6350351B2 (es) 1978-01-28 1988-10-07 Sheru Intern Risaachi Maachatsupii Bv
US4407803A (en) 1981-08-17 1983-10-04 Abbott Laboratories Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
DE3413078A1 (de) 1984-04-06 1985-10-24 Miles Laboratories, Inc., Elkhart, Ind. Chromogene aminosaeure- und peptidester, verfahren zu deren herstellung, verwendung dieser verbindungen in analysenverfahren sowie mittel zum nachweis esterolytischer und/oder proteolytischer enzyme
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4761419A (en) 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DK611489A (da) 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
DE3905908A1 (de) * 1989-02-25 1990-09-06 Bayer Ag Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
DE3908298A1 (de) 1989-03-14 1990-09-20 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-n,n'-sulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3927369A1 (de) 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
DE3927931A1 (de) 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
DE3927930A1 (de) 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
DE3935139A1 (de) 1989-10-21 1991-04-25 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-thioharnstoffe
DE3935491A1 (de) 1989-10-25 1991-05-02 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
JPH04182469A (ja) 1990-11-16 1992-06-30 Terumo Corp 新規なチオエステル化合物
JP2696150B2 (ja) 1991-02-05 1998-01-14 株式会社大塚製薬工場 キノリン誘導体
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
DE4105551A1 (de) 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4139751A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
DE4112533A1 (de) 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
CA2108014A1 (en) 1991-04-26 1992-10-27 Ernest S. Hamanaka 4-aryl-3-(heteroarylureido)quinoline derivatives
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
DE4128681A1 (de) 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP3130342B2 (ja) 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JPH05128327A (ja) 1991-11-01 1993-05-25 Mitsubishi Electric Corp Ｉｃカード
JPH05130897A (ja) 1991-11-11 1993-05-28 Terumo Corp チオール化合物測定用試薬組成物
DE4139750A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe
DE4139749A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenyl-essigsaeureamide
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5183825A (en) 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
EP0570112A1 (en) 1992-04-23 1993-11-18 Zeneca Limited Cycloalkane derivatives
DE4226519A1 (de) 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
JPH0692939A (ja) 1992-09-16 1994-04-05 Kyowa Hakko Kogyo Co Ltd イミダゾール誘導体
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
ATE163412T1 (de) * 1993-06-08 1998-03-15 Sanofi Sa Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren
JPH0710870A (ja) 1993-06-23 1995-01-13 Asahi Glass Co Ltd 新規アミノピリジン誘導体およびその塩
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
CN1048731C (zh) * 1993-09-17 2000-01-26 史密丝克莱恩比彻姆公司 编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
US5453509A (en) 1993-10-08 1995-09-26 Synaptic Pharmaceutical Corporation Functionalization of acyl pyridinium salts
DE4411657A1 (de) 1994-04-02 1995-10-05 Basf Ag Verfahren zur Herstellung von 6-Hydroxymethylchinolinen
FR2722198B1 (fr) 1994-07-08 1996-10-04 Pf Medicament 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE19500122A1 (de) 1995-01-04 1996-07-11 Bayer Ag Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan
SK1296A3 (en) 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
DE19532714A1 (de) 1995-09-05 1997-03-06 Bayer Ag Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden
JPH1067658A (ja) 1995-09-13 1998-03-10 Takeda Chem Ind Ltd 免疫抑制剤
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
NZ332341A (en) 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
EP0808627A2 (de) 1996-05-22 1997-11-26 Hoechst Aktiengesellschaft Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
JPH101471A (ja) 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
WO1998014430A1 (en) 1996-10-02 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
ATE246184T1 (de) 1996-11-06 2003-08-15 Darwin Discovery Ltd Chinoline und deren therapeutische verwendung
WO1998034115A1 (en) 1997-02-04 1998-08-06 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0991623A2 (en) 1997-06-19 2000-04-12 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AR016294A1 (es) 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6538022B1 (en) 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
CA2392568A1 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
WO2001056552A2 (en) 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064218A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
WO2001064252A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1261348A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
JP2003525239A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
EP1267929A2 (en) 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064226A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397253A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001070227A1 (en) 2000-03-17 2001-09-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2001070228A1 (en) 2000-03-17 2001-09-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2001261654A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6495562B1 (en) 2000-04-25 2002-12-17 Abbott Laboratories Naphthamidine urokinase inhibitors
WO2001082917A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6949656B2 (en) 2000-08-08 2005-09-27 Shionogi & Co., Ltd. Cyclic amine derivatives and use thereof
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
JP4287649B2 (ja) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
WO2002030407A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
EP1339407B1 (en) 2000-11-28 2006-04-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
WO2002085364A1 (en) 2001-04-25 2002-10-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
ES2296928T3 (es) 2001-05-03 2008-05-01 The University Of Chicago Receptores x hepaticos.
US6693134B2 (en) 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
EP1426046A4 (en) * 2001-09-14 2005-11-02 Shionogi & Co NEW USE OF TRICYCLIC COMPOUNDS
AU2002336433A1 (en) 2001-10-08 2003-04-22 Eli Lilly And Company Tricyclic compounds useful for modulating lxr
AU2003220521A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators

Also Published As

Publication number Publication date
JP2007516258A (ja) 2007-06-21
KR20070001922A (ko) 2007-01-04
WO2005058834A3 (en) 2005-11-17
WO2005058834A2 (en) 2005-06-30
US7576215B2 (en) 2009-08-18
NO20062561L (no) 2006-09-08
PA8619901A1 (es) 2005-11-25
AU2004298486A1 (en) 2005-06-30
SV2005001973A (es) 2005-11-04
EP1692111A2 (en) 2006-08-23
TW200529845A (en) 2005-09-16
IL175892A0 (en) 2006-10-05
ECSP066635A (es) 2006-10-25
AR047329A1 (es) 2006-01-18
EP2284157A1 (en) 2011-02-16
RU2006124843A (ru) 2008-01-20
CA2547518A1 (en) 2005-06-30
CR8410A (es) 2006-10-04
BRPI0417543A (pt) 2007-03-27
US20050131014A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
PE20050676A1 (es) Quinolinas referidas a enfermedades cardiovasculares
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
PE20160540A1 (es) Inhibidores de bromodominios
ECSP066695A (es) Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1
ECSP077171A (es) Inhibidores de polimerasa viral
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
PE20090773A1 (es) Derivados de morfolina pirimidina
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
EA200800182A1 (ru) Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR051485A1 (es) Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
PE20040832A1 (es) Derivados de indolil pirazinona
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos

Legal Events

Date Code Title Description
FC Refusal